Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

J Clin Med · 2026 · PMC13362465 · PMID 42452335

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

borderline significantp = 0.053so close (0.05 < p ≤ 0.1)

Within-group longitudinal analyses across 2 time points (by the Wilcoxon signed-rank test) confirmed stable over time TNF-α levels in the evolocumab group (all p > 0.1), whereas in the control group a borderline significant increase was observed at 72 h vs. baseline ( p = 0.053) ( Supplementary Table S2 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.